Peru - espanja - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

marketing y ventas vital sociedad anonima cerrada - solucion para inyeccion

Peru - espanja - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

marketing y ventas vital sociedad anonima cerrada - solucion para inyeccion

Chile - espanja - ISPC (Instituto de Salud Pública de Chile)

novartis chile s.a. - sin formulas

Euroopan unioni - espanja - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mieloma múltiple - agentes antineoplásicos - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopan unioni - espanja - EMA (European Medicines Agency)

paion deutschland gmbh - la angiotensina ii acetato - hypotension; shock - agentes que actúan sobre el sistema renina-angiotensina - giapreza está indicado para el tratamiento de la hipotensión refractaria en adultos con sépticos u otros shock distributivo que permanecen hipotensión a pesar de un volumen adecuado de la restitución y de la aplicación de las catecolaminas y otras terapias vasopresor.

Euroopan unioni - espanja - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mieloma múltiple - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopan unioni - espanja - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - mieloma múltiple - agentes antineoplásicos - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopan unioni - espanja - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - agentes antineoplásicos - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Euroopan unioni - espanja - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - agentes antineoplásicos - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Euroopan unioni - espanja - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - linfoma, folicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.